A CFer who I is listed for transplant and who I respect and admire so much, Piper, recently posted a blog which you can read HERE . She discusses positivity and questions how CFers, at different stages of the disease, can understand it. She got me thinking about how all CFers as well as non-cfers can universally understand each other's take on being positive. Before I begin my discussion I want to make a Disclaimer that this blog is in no way meant to offend anyone but rather to bring together the CF community in discussion.First let me make a couple points:1. CF is a confusing disease in the sense that it affects everyone differently. There are many factors contributing to this difference including environmental factors, upbringing, bacteria, access to healthcare and technology, age, biology, genetics (both with the CF gene and others), compliance, lifestyle, and just plain luck. Some people with CF may appear perfectly healthy, some run marathons, some have never been in the hospital, some have received transplants and are living healthy lifestyles, some live on oxygen every day, some spend half of their year or more in the hospital, some are preparing for transplants, and unfortunately still some don't make it past the age of 16, or 20, or 30 (and we pray for the families and lives of those people every day). The fact is, it affects everyone differently and although there are some people who are non-compliant, there are also people who try their best to be healthy and still end up sick.2. It has been my own personal experience that if I do everything I am supposed to as far as compliance and exercise, that I am one of the "lucky" ones. But this is taking into account that I go to clinic and have been admitted to a world renown hospital in Boston, I was diagnosed very young (although not at birth), I have been lucky enough to always have good insurance that enables me to have the best treatments possible, I live a lifestyle that is not detrimental to my health (i.e. I have not yet begun to work full time), and I am young. I have had medicines like pulmozyme and tobi for the majority of my life, I have had access to the vest since I was 7. Yet, before I started to be religious about doing my treatments and exercising, I was in the hospital two or more times a year for 2 or 3 weeks at a time (and not just for routine things, I've had severe hymoptisis, i've been on oxygen, been to the ICU, been so sick I could barely talk, etc.) I also had my fair share of skipping treatments (sometimes for a week at a time) of cheating (dumping out my nebs, shortening my vest, not taking my pills) of not exercising, of being lazy. And I saw, as a direct result of that, a lot more time spent feeling sick and being in the hospital.3. Although it is difficult to compare someone with CF who is virtually symptomless and someone who is getting new lungs, there should still be respect for the lives that we all live. There is still a baseline of numerous amounts of treatments and therapies that all CFers must do to keep themselves healthy. The disease is still progressive and just because someone may be healthy now, it doesn't mean their disease might not take a turn for the worst at any moment. (And vice versa, it doesn't always mean that just because someone is unhealthy now they can't get better)I think that as a CF community we all need to respect the fact that our disease affects each of us differently, sometimes we don't have control over it, but that doesn't mean that we should ever stop trying to make ourselves better, like Piper said "here's to trying." We can still be inspired by each other's fights even when one of us is sicker than the other if we respect and understand how differently CF can affect some people. I stress compliance and exercise a lot in my blog because ...
Saturday, March 13, 2010
Another Great Positivity Blog
Friday, March 12, 2010
How to Raise a Child with CF
Post:
Let me start by asking that no one give me the pat answer of "treat your CF kid the same as the non-CF kids" I know that in an ideal world we could pretend the CF doesn't exist and place the child rearing ahead of the CF, but the reality is that my first priority for my daughter is making sure she gets all of her CF treatments.
I'm really running into a problem with my three year old and discipline. Yeah, some of it is the age, but some of it is due to the fact that she is pretty spoiled in several areas. There are lots of things that I don't say "no" about for her. Its not about purposefully spoiling her -- but rather about fighting the important battles first. Alyssa HATES to do her vest and its a huge production every night. The only thing that works to keep her quiet and not ripping the tubes out or shutting off the machine is to let her pick the tv show we are watching. This means that at treatment time, whatever her brothers are watching turns off for the sake of keeping her treatment complete.
Another example is food. Alyssa has to eat like a CF kiddo, and that means that I allow her to have a wider choice of foods. If she doesn't like what I've made I try to accommodate her, if she doesn't eat dinner, she can still have ice cream afterwards. Different rules apply to her and the boys know it and deal with it.
But the problem is that she is beginning to see that different rules apply to her and they are spilling into all the other areas of life. She instigates issues with her brothers (they walk by, she pushes them or she purposefully pulls a toy out of their hand, or she throws a fit when the tv show is not "hers"). All of these not CF things get handled promptly by me. She gets a warning (unless she hits) and then a time out, but it doesn't change her behavior at all. Some days she'll get 10 different time outs (in her room). I talk to her all the time about good behavior and give lots of positive reinforcement for when she does share. But you can't exactly sing the praises of a kid who didn't hit their brother this time.
I'm going nuts here. And I know that a lot of this is because of the CF and how it changes the rules, but I just don't know what to do about it. I'd love some insight from those who have been there.
My response:
I have no CF children. I however have CF and think that my mom did quite possibly the best job ever. So of course with my advice, you can take it or leave it...
I would never ever ever say "because of CF". If you think you have problems now, wait until she's interacting in the real world where nobody gives you special privileges "because of CF". My mom treated me no different than my brothers. CF wasn't a central focus in my house. Yeah, I was a sick kid at times and had to go in the hospital and do my treatments 3 times a day, ok, so what? I was still a kid. I still got disciplined the way my brothers got disciplined (except a lot more cause I was a brat).
She's not eating the ice cream "because she has CF". She's eating it because she's 3 and likes ice cream. Don't finish your plate, no ice cream. If you're concerned about your daughter getting enough calories, there are powders you can put in milk that will add nutrition and calories. High fat and high sugar foods aren't the only way to pack on the calories. You can do it many other ways without her even knowing.
How do you handle your other kids when they disobey? Do the same thing for her. We are who we are; CF doesn't make us who we are. If she's this way with CF, she'd be this way without.
Schedule treatment time for the same time every night, that way, the boys can pick the show before it, and then when it's treatment time it's her turn. Simply allowing her more options and priority "because of CF" is going to create a monster.
I also agree that taking away something important to a child is usually the best option for discipline. At least, I know that's what worked for me, and I was a crazy kid.
Bottom line: I would treat a CFer no differently than his/her brothers or sisters. Life isn't going to be fair her whole life and that's not changing. Life isn't fair for all non-CFers as well. A lot of it is her age, but I really think you need to nip it in the bud before her whole mentality is shaped into "I have CF, therefore, my way or the highway".
With all of that said...I have no kids and I talk a big game now, but who knows how I'll respond until I'm in the situation. Just know that I get that and I'm just trying to help.
Ronnie
Was I too harsh? What would your advice be?
Thursday, March 11, 2010
What Does Being "Positive" Mean to You?
What does "positivity" mean to you in the context of CF, or life in general?
I feel like "positive attitude," "positivity," and other words get thrown around a lot by really amazing and well-meaning people, but I'm not sure everyone's version of what it means to be "be positive" is really the same. I mean, I highly doubt many people see themselves as having a "negative attitude" for example -- they may see themselves as being "realistic" or even "honest," and in turn they may think that others are unduly cheerful or even "in denial." And I guess this all got me thinking, because is one person's positive thinking another person's denial? Or is my realism your negativity?
And even more vexing, is our "hope" or "positivity" threatened by stories that don't fit into our paradigm? Or is our sense of self and worth degraded when others do better than we have with the same disease?Please click here to continue to read this fantastic blog post!
Wednesday, March 10, 2010
Wash Sprints
Tuesday, March 9, 2010
Smog in the City
Monday, March 8, 2010
When Tune-Ups Don't "Fit"
Sunday, March 7, 2010
Saturday, March 6, 2010
Exciting Article About Drug Delivery
Beating the cystic fibrosis barrier
Biodegradable nanoparticles capable of penetrating the mucus barrier in the lungs and gut of cystic fibrosis (CF) sufferers have been developed by researchers at John Hopkins University, led by Justin Hanes, professor of chemical and biomolecular engineering.
“Cystic fibrosis mucus is notoriously thick and sticky, and represents a huge barrier to aerosolised drug delivery,” said Pamela Zeitlin, CF expert and professor of paediatrics, who collaborated on the study. “Nanoparticles were engineered to travel through cystic fibrosis mucus at a much greater velocity than ever before, thereby improving drug delivery,” she said.
The nanoparticles comprise of two parts made of molecules regularly used in existing medications. An inner core of polysebacic acid (PSA) traps therapeutic agents inside while a dense outer coating of polyethylene glycol (PEG) molecules allows the particle to move through the mucus by preventing it from reacting with proteins.
Hanes previously demonstrated that latex coated with PEG could slip past mucus coatings, but because the body could not break it down into harmless components it was impractical. “The major advance here is that we were able to make biodegradable nanoparticles that can rapidly penetrate thick and sticky mucus secretions and that these particles can transport a wide range of therapeutic molecules,” said Hanes.
The nanoparticles have potential applications treating lung and cervical cancers, and inflammation of the sinuses, eyes, lungs and gastrointestinal tract where mucus is produced to protect sensitive areas, said Benjamin C Tang, lead author and postdoctoral fellow in the department of chemical and biomolecular engineering. Zeitlin concludes: “This work is critically important to moving forward with the next generation of small molecule and gene-based therapies.”
Read the full article here: http://www.labnews.co.uk/laboratory_article.php/5285/2/beating-the-cystic-fibrosis-barrier
Friday, March 5, 2010
My First Experience with Hemoptysis
Thursday, March 4, 2010
Rondi Sings "Girls Just Wanna Have Fun"
Wednesday, March 3, 2010
The Ebbs and Flows of Running
Tuesday, March 2, 2010
Top Ten Favorite "Reality" Shows
Monday, March 1, 2010
Engagement Photos Slideshow
Sunday, February 28, 2010
One Happy Couple
Saturday, February 27, 2010
Smart Pseudomonas
Adapting To Clogged Airways Makes Common Pathogen Resist Powerful Antibiotics
People with cystic fibrosis frequently have lung infections that defy treatment. Cystic fibrosis is an inherited disease that clogs airways with thick mucous. While the life expectancy for children with cystic fibrosis has increased over the past few decades, many lives are still shortened in young adulthood by the ravages of lung infections.
These chronic infections are often caused by common, environmental microbes that mutate in ways that let them live and thrive in viscous lung secretions. The same adaptations also make the pathogens less likely to be killed off by powerful antibiotics, according to a recent study led by Dr. Lucas “Luke” Hoffman, University of Washington assistant professor of pediatrics.
Surprisingly, he added, the pathogens don’t need any previous exposure to the antibiotics to resist their effects. The results were published in the latest edition of PLoS Pathogen.
The researchers looked at Pseudomonas aeruginosa, a microbe that can infect a cystic fibrosis patient early in life and then undergo various changes as it establishes a chronic lung infection. Pseudomonas aeruginosa with specific alterations tend to give patients a poor outcome. Some of those alterations diminish the chances of eradicating the infection with antibiotics.
It’s believed that these adaptive alterations in Pseudomonas, all of which are caused by genetic changes, could be selected for by the environment inside a patient’s airways, the researchers noted. Characteristics that facilitate microbial survival begin to emerge.
The specific airway conditions that select for these genetic changes, Hoffman said, remain unclear. “But,” he added, “we have some clues from what is known about airway mucus.”
From the point of view of Pseudomonas, the physical properties of cystic fibrosis mucus, Hoffman said, “make it a great place for the stuff people routinely breathe in to set up shop.” Cystic fibrosis secretions contain a lot of nitrates and amino acids, which Pseudomonas can use to grow.
Inside mucus plugs oxygen levels are low. Some Pseudomonas strains can live in this oxygen-poor, nutrient-rich environment. Hoffman and his team found that a mutation that occurs commonly in Pseudomonas from cystic fibrosis patients allows the pathogen to grow better in the nutrient environment in cystic fibrosis secretions. This particular mutation inactivates a gene named lasR. Pseudomonas with this mutation apparently undergo a metabolic shift: consuming less oxygen while utilizing nitrate more efficiently. lasR mutant bacteria also can handle oxidative stress resulting from an imbalance of damaging substances called free radicals forming faster than they can be detoxified.
One source of oxidative stress encountered by Pseudomonas is the antibiotic treatment that is frequently given to people who have cystic fibrosis. Antibiotics like ciprofloxacin and tobramycin kill bacteria partly by inducing the overproduction of free radicals and causing oxidative stress. Hoffman and his team found that, because these mutant microbes are resistant to oxidative stress, they were relatively resistant to these antibiotics when grown in conditions that were like cystic fibrosis mucus.
“We learned that simply by adapting to the conditions inside the airways of cystic fibrosis patients, mutated Pseudomonas can withstand the effects of ciprofloxacin and tobramycin,” Hoffman said. They did not need any previous exposure to these antibiotics to reduce their susceptibility.
Hoffman and his team suspect that Pseudomonas is not the only microbe that can do this. Some of the characteristics conferred by the mutation in Pseudomonas are also exhibited in other microbes found in chronic lung infections, such as tuberculosis or the fungal pathogen, Cryptococcus neoformans, Hoffman noted. Metabolic shifts may be a way many microbes get the upper hand over their hosts — and over antibiotics.
This report, Hoffman said, may point to new ideas for treating chronic lung infections. Luckily, colonies of Pseudomonas with the lasR mutation are relatively easy to identify in hospital laboratories by their distinctive iridescent sheen. Because lasR mutant Pseudomonas has been associated with worse outcomes in cystic fibrosis patients, indentifying Pseudomonas with the lasR mutation may be of prognostic value and may indicate the need for treatment with specific antibiotics like monobactams, tetracyclines, or polymyxin, whose mode of action differs from ciprofloxacin and tobramycin. Other treatment methods may be targeted at preventing adaptive changes, such as the lasR mutation, in Pseudomonas, the researchers said.
Friday, February 26, 2010
First Time Finding the Baby in a Cake
Thursday, February 25, 2010
Thankful for New Drugs!!!
This Thankful Thursday is a pretty easy one! I'm so thankful for the new drug just approved by our FDA :) I've heard nothing but great things about this drug from fellow cysters and fibros and I really can't wait to try it out myself. Make sure to call your clinic ASAP to see if this is a drug that can help you and one that you can get on sooner rather than later.
The drug by the way is Cayston, also known as AZLI. Think of it as another TOBI type of drug that can be done during your off month of TOBI or can be done instead of TOBI all together. It has to be taken three times a day, but the great part is, the treatment takes 2 to 3 minutes!!!
Bring it on!
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R) (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). Cayston's safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second (FEV1) of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.
Cayston is administered at a dose of 75 mg three times daily over a 28-day period and is delivered via the Altera(R) Nebulizer System, a portable, drug-specific delivery device using the eFlow(R) Technology Platform, developed by PARI Pharma GmbH. PARI Pharma also contributed to the development of Cayston's drug formulation for delivery with the Altera Nebulizer System. Cayston will be available in the United States by the end of next week through certain specialty pharmacies.
"All of us at Gilead extend our thanks to the investigators and to the people with cystic fibrosis who took part in the Cayston clinical trials," said Norbert Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to making Cayston available to the cystic fibrosis community as soon as possible."
CF is a chronic, debilitating genetic condition that affects the respiratory and digestive systems of approximately 70,000 people worldwide, including 30,000 people in the United States. Chronic respiratory tract infection with P. aeruginosa contributes to the decline in pulmonary function, which is often associated with morbidity and mortality among CF patients.
"Since its founding in the 1950s, the Cystic Fibrosis Foundation has worked to advance the care and treatment of cystic fibrosis and we are pleased with the progress to date," said Robert J. Beall, PhD, President and Chief Executive Officer, Cystic Fibrosis Foundation. "However, a significant need for new treatments remains for people with cystic fibrosis, particularly for those with chronic pseudomonal infection. As the first new inhaled antibiotic approved for use in cystic fibrosis in more than a decade, Cayston therefore represents an important therapeutic option in the care of patients with cystic fibrosis."
Cayston received conditional marketing authorizations in the European Union and Canada in September 2009 and was approved in Australia in January 2010. Applications for marketing approval of Cayston are currently pending in Switzerland and Turkey.
Reimbursement and Access to Care
Gilead also announced today the establishment of a program designed to minimize barriers to access for Cayston for uninsured, privately insured and government-insured people with cystic fibrosis.
Additionally, Gilead is launching the Cayston(R) Access Program, a call center developed with Cystic Fibrosis Foundation Pharmacy, LLC, a wholly owned subsidiary of the Cystic Fibrosis Foundation. The program will assist people with cystic fibrosis and members of their care team with insurance verification, referral to participating specialty pharmacies, claims support and co-pay assistance. For information about the Cayston Access Program, call 1-877-7CAYSTON (877-722-9786) or visit www.cayston.com.
About Cayston
Cayston (aztreonam for inhalation solution) 75 mg is an inhaled antibiotic for patients with cystic fibrosis who have P. aeruginosa. Aztreonam has potent in vitro activity against gram-negative aerobic pathogens including P. aeruginosa. Cayston contains aztreonam formulated with lysine, a proprietary formulation of aztreonam developed specifically for inhalation. Aztreonam formulated with arginine has previously been approved by FDA for intravenous administration.
Cayston is administered three times a day for a 28-day course, followed by 28 days off of Cayston therapy. Cayston is administered by inhalation and should only be used with an Altera Nebulizer System. Patients should use a bronchodilator before administration of Cayston.
Article from Business Wire. February 22, 2010. To read the full article please click here.
Tuesday, February 23, 2010
Top Ten Toys I Never Grew Out Of
(**Written by Mandi)








Monday, February 22, 2010
Pre-marriage Counseling by Rondi
Sunday, February 21, 2010
Drug Improved Survival in Mice With Cystic Fibrosis
In the search for new treatments for cystic fibrosis, U.S. researchers have identified a defective signaling pathway that contributes to the severity of the inherited lung disease.
Cystic fibrosis causes thick, sticky mucus to build up in the lungs and digestive tract, and is one of the most common potentially lethal genetic diseases in children and young adults.
In the new study, the researchers found that correcting the defective signaling pathway for a protein called peroxisome proliferator-activated receptor-y (PPAR-y) reduced cystic fibrosis symptoms in mice.
"Cystic fibrosis results from a genetic mutation in a channel, or membrane pore, that facilitates the transport of chloride and bicarbonate electrolytes from inside the cell to the spaces outside the cell," lead investigator Dr. Gregory Harmon, of the University of California, San Diego School of Medicine, said in a news release from the school.
"Loss of the cystic fibrosis pore channel results in inflammation and mucus accumulation. It also results in dehydration of the cell surfaces that make up the lining spaces inside the lungs and other affected organs, such as the intestinal tract," he explained.
Working with cells from mice and human cell lines from cystic fibrosis patients, Harmon and his colleagues determined that multiple genes affected by PPAR-y were reduced in cystic fibrosis.
The researchers then treated mice with cystic fibrosis with the drug rosiglitazone (a drug that binds and activates PPAR-y) and found that gene expression was largely normalized and survival improved. Among the other findings:
- Drug treatment also corrected part of the inflammatory process associated with cystic fibrosis.
- Deleting PPAR-y in the intestine of mice worsened cystic fibrosis.
- Activating PPAR-y can increase bicarbonate production in intestinal tissue by increasing the activity of bicarbonate-producing enzymes called carbonic anhydrases.
"For the first time, we are able to use a drug that activates bicarbonate transport without affecting chloride transport, and see improvement in the disease," Harmon said.
The findings, published in the Feb. 14 issue of Nature Medicine, may lead to new treatments for cystic fibrosis.
Find original article at http://www.palmbeachpost.com/health/drug-improved-survival-in-mice-with-cystic-fibrosis-253691.html

